Sleep | Phase II Developments | Pipeline Prospector

Pfizer Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Contact Supplier

Virtual Booth

Pharmavenue, Spain 2020

Participation Not Confirmed

Update your events

Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for...

Lead Product(s): Reboxetine

Therapeutic Area: Sleep

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Axsome Therapeutics

Deal Size: $331.0 million Upfront Cash: $3.0 million

Deal Type: Licensing Agreement January 13, 2020

Details:

Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy which expands Axsome’s pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia

Adare Pharmaceuticals

Virtual Booth Transforming oral delivery challenges into proprietary product solutions.

United States

Contact Supplier

Virtual Booth

Pharmavenue, Spain 2020

Participation Not Confirmed

Update your events

Adare Pharmaceuticals and NLS Pharmaceutics Collaborate to Develop Mazindol Controlled Release (CR) for the Treatment of ADHD and Narcolepsy

Lead Product(s): Mazindol

Therapeutic Area: Sleep

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: NLS Pharmaceutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 13, 2020

Details:

NLS Pharmaceutics entered a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and ADHD utilizing Adare’s proprietary modified release technologies.

Umecrine Cognition

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

Pharmavenue, Spain 2020

Participation Not Confirmed

Update your events

Karolinska Development’s Portfolio Company Umecrine Cognition Presents Positive Additional Results From A Phase 2a Study Of Golexanolone

Lead Product(s): Golexanolone

Therapeutic Area: Sleep

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 08, 2020

Details:

Analyses of data for additional efficacy endpoints reveal that treatment with the golexanolone exerts a significant effect on brain signaling with a positive effect on excessive daytime sleepiness.

Find

Find Drugs for Sleep in Phase II Clinical Development

Phase II

A collaboration with SCORR Marketing

Product Type

Companies

Pfizer Inc

Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for...

Adare Pharmaceuticals

Adare Pharmaceuticals and NLS Pharmaceutics Collaborate to Develop Mazindol Controlled Release (CR) for the Treatment of ADHD and Narcolepsy

Umecrine Cognition

Karolinska Development’s Portfolio Company Umecrine Cognition Presents Positive Additional Results From A Phase 2a Study Of Golexanolone